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Background: Obesity is an important risk factor for atrial fibrillation (AF). Leptin is an important adipokine. However,
it is not clear whether leptin directly modulates the electrophysiological characteristics of atrial myocytes.
Results: Whole cell patch clamp and indo-1 fluorescence were used to record the action potentials (APs) and ionic
currents in isolated rabbit left atrial (LA) myocytes incubated with and without (control) leptin (100 nM) for 1 h to
investigate the role of leptin on atrial electrophysiology. Leptin-treated LA myocytes (n = 19) had longer 20% of AP
duration (28 ± 3 vs. 21 ± 2 ms, p < 0.05), but similar 50% of AP duration (51 ± 4 vs. 50 ± 3 ms, p > 0.05), and 90% of
AP duration (89 ± 5 vs. 94 ± 4 ms, p > 0.05), as compared to the control (n = 22). In the presence of isoproterenol
(10 nM), leptin-treated LA myocytes (n = 21) showed a lower incidence (19% vs. 54.2%, p < 0.05) of delayed
afterdepolarization (DAD) than the control (n = 24). Leptin-treated LA myocytes showed a larger sodium current,
but a smaller ultra-rapid delayed rectifier potassium current, and sodium-calcium exchanger current than the
control. Leptin-treated and control LA myocytes exhibited a similar late sodium current, inward rectifier potassium
current, transient outward current and L-type calcium current. In addition, the leptin-treated LA myocytes (n = 38)
exhibited a smaller intracellular Ca2+ transient (0.21 ± 0.01 vs. 0.26 ± 0.01 R410/485, p < 0.05) and sarcoplasmic
reticulum Ca2+ content (0.35 ± 0.02 vs. 0.43 ± 0.03 R410/485, p < 0.05) than the control LA myocytes (n = 42).
Conclusions: Leptin regulates the LA electrophysiological characteristics and attenuates isoproterenol-induced
arrhythmogenesis.
Keywords: Adipokines, Atrial fibrillation, Epicardial fat, Leptin, ObesityBackground
Obesity is an independent risk factor for the genesis of AF
[1-4]. Atrial fibrillation (AF) is the most prevalent cardiac
arrhythmia in clinical practice which can induce cardiac
dysfunction and stroke [5]. Obesity increase the preva-
lence of hypertension, ischemic heart disease, congestive
heart failure, and ventricular dysfunction, which can con-
tribute to the development of AF [6-9]. In addition,
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stated.increasing inflammation, mechano-electrical regulation
and adipocyte-myocytes interaction [10]. Adipose tis-
sues can produce many adipokines, which may have
electrophysiolgical effects through changing action po-
tential morphology, ionic profiles and contractility in
the atrium [11,12]. However, it is not clear which adi-
pokine is responsible for the cardiac effects of adipose
tissues.
Leptin is a peptide hormone that is expressed in adi-
pose tissue, and that regulates body weight through the
inhibition of food intake and promotion of energy ex-
penditure [13,14]. However, leptin can also be produced
in the heart, and function in an autocrine and paracrine
manner [15,16]. Leptin plasma concentrations are in-
creased in insulin-resistant states, such as obesity and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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elevated in patients with heart disease such as ischemic
heart disease and congestive heart failure [20,21]. How-
ever, clinical studies have yielded inconsistent results on
the association of leptin with cardiovascular disease
[20,22]. Evidences have indicated that leptin may have
either adverse or beneficial effects on the heart and the
vascular system [23-27]. In addition, leptin is considered
a novel link between obesity, diabetes, cardiovascular
risks and ventricular hypertrophy [28]. Leptin signaling
has been shown to contribute to atrial fibrosis and
angiotensin II-evoked AF [29]. These findings suggest
that leptin may play a critical role in cardiac electrophysi-
ology. The purpose of this study was to investigate the ef-
fect of leptin on the electrophysiological characteristics of
atria myocytes and its role in atrial arrhythmogenesis.
Methods
Isolation of single LA myocytes
All animal experimental procedures were approved by
the Institutional Animal Care and Use Committee (IACUC)
at Taipei Medical University (Protocol Number LAC-100-
0127) and conform to the institutional Guide for the Care
and Use of Laboratory Animals and the Guide for the Care
and Use of Laboratory Animals published by the US Na-
tional Institutes of Health (NIH Publication No. 85-23, re-
vised 1996). Male rabbits (1 to 2 kg) were intravenously
injected with sodium pentobarbital (100 mg/kg). After
anesthetization, the hearts were immediately removed and
mounted on a Langendorff apparatus to perform retrograde
perfusion of oxygenated normal Tyrode’s solution at 37°C
containing (in mM): NaCl 137, KCl 5.4, CaCl2 1.8, MgCl2
0.5, HEPES 10 and glucose 11; adjusted to pH 7.4 with
NaOH. After the hearts were cleaned of blood, the perfusate
was replaced with oxygenated Ca2+-free Tyrode’s solution
containing 300 units/ml collagenase type I (Sigma Chemical,
St, Louis, MO) and 0.25 units/ml protease type XIV (Sigma)
for approximately 8 to12 min. The left atrium (LA) was ex-
cised and gently shaken in 50 ml of Ca2+-free oxygenated
Tyrode’s solution until single cardiomyocytes were obtained.
The solution was then gradually changed to normal
oxygenated Tyrode’s solution. The myocytes were allowed
to stabilize in the bath for at least 30 min before the
experiments.
Electrophysiological study
A whole-cell patch clamp was performed in the LA
myocyte with and without (control) incubation of leptin
(100 nM) for 1 h using an Axopatch 1D amplifier
(Axon Instruments, CA, USA) at 35±1°C as described
previously [11,30,31]. Borosilicate glass electrodes (o.d.,
1.8 mm) were used, with tip resistances of ~ approximately
3 to 5 MΩ. Before formation of the membrane-pipette
seal, the tip potentials were zeroed in Tyrode’s solution.Junction potentials between the bath and pipette solution
(9 mV) were corrected for action potential (AP) record-
ings. APs were recorded in the current-clamp mode, and
ionic currents were measured in the voltage-clamp mode.
A small hyperpolarizing step from a holding potential
of -50 mV to a testing potential of -55 mV for 80 ms was
delivered at the beginning of each experiment. The area
under the capacitive currents was divided by the applied
voltage step to obtain the total cell capacitance. Normally,
60%-80% series resistance (Rs) was electronically compen-
sated. The resting membrane potential (RMP) was mea-
sured during the period between the last repolarization
and the onset of the subsequent AP. The AP amplitude
(APA) was obtained from the measurement of RMP to the
peak of the AP depolarization. AP durations were mea-
sured at 20% (APD20), 50% (APD50), and 90% (APD90) re-
polarization of the amplitude at a driven rate of 1 Hz.
DADs (delayed afterdepolarizations) were defined as the
presence of a spontaneous depolarization of the impulse
after full repolarization had occurred.
Micropipettes were filled with a solution containing
the following (in mM): CsCl 130, MgCl2 1, Mg2ATP 5,
HEPES 10, EGTA 10, NaGTP 0.1, and Na2 phosphocrea-
tine 5, titrated to a pH of 7.2 with CsOH for the experi-
ments on the L-type calcium current (ICa-L); containing
(in mM) CsCl 133, NaCl 5, EGTA 10, Mg2ATP 5, TEACl
20, and HEPES 5 (pH 7.3 with CsOH) for the sodium
current (INa); containing (in mM) 10 NaCl, 130 CsCl, 5
EGTA, 5 HEPES, 5 glucose, and 5 ATP-Mg for the late
sodium current (INa-Late); containing (in mM) NaCl 20,
CsCl 110, MgCl2 0.4, CaCl2 1.75, tetraethylammonium
chloride (TEACl) 20, BAPTA 5, glucose 5, Mg2ATP 5,
and HEPES 10, titrated to a pH of 7.25 with CsOH for
the experiments on sodium-calcium exchanger (NCX)
current; and containing (in mM) KCl 20, K aspartate 110,
MgCl2 1, Mg2ATP 5, HEPES 10, EGTA 0.5, LiGTP 0.1, and
Na2 phosphocreatine 5, titrated to a pH of 7.2 with KOH
for the experiments on the AP and potassium currents.
The INa was recorded during depolarization from a
holding potential of -120 mV to testing potentials ran-
ging from -90 to 0 mV in 10-mV steps for 40 ms at a
frequency of 3 Hz at room temperature (25 ± 1°C) with
an external solution containing (in mM): NaCl 5, CsCl
133, MgCl2 2, CaCl2 1.8, nifedipine 0.002, HEPES 5 and
glucose 5 with a pH of 7.3. The INa-Late was recorded at
room temperature with an external solution containing
(in mM): 140 NaCl, 5 CsCl, 2.0 MgCl2, 1.8 CaCl2, 5
HEPES, 5 glucose, and 0.002 of nicardipine. The ampli-
tude of the INa-Late was measured at a voltage of -20 mV
as the mean current amplitude between 200 and 250 ms
after the membrane was depolarized by a 2,000-ms pulse
from -140 to -20 mV.
The ICa-L was measured as an inward current during
depolarization from a holding potential of −50 mV to
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steps for 300 ms at a frequency of 0.1 Hz using a perfo-
rated patch clamp with amphotericin B. The NaCl and
KCl in the external solution were replaced with tetra-
ethylammonium chloride and CsCl, respectively.
The transient outward current (Ito) was studied with
a double-pulse protocol. A 30-ms prepulse from −80
to −40 mV was used to inactivate the sodium channels,
followed by a 300-ms test pulse to +60 mV in 10-mV
steps at a frequency of 0.1 Hz. CdCl2 (200 μM) was
added to the bath solution to inhibit ICa-L. The Ito was
measured as the difference between the peak outwardFigure 1 Effect of leptin on the left atrial (LA) electrical activity and e
(LA) myocytes. A. Examples and average data of the action potential from
Leptin-treated LA myocytes had longer APD20. B. Examples of isoprotereno
incidence of isoproterenol-induced DADs from control (n = 24) and leptin-t
potential amplitude, APD90 90% action potential duration, APD50 50% action p
control LA myocytes.current and steady-state current. The ultra-rapid delayed
rectifier potassium current (IKur) was studied with a
double-pulse protocol, consisting of a 100-ms depolarizing
pre-pulse to +40 mV from a holding potential of -50 mV,
followed by 150-ms voltage steps from -40 to +60 mV in
10 mV increments at room temperature to provide an
adequate temporal resolution. The IKur was measured
as 4-aminopyridine (1 mM) sensitive currents.
The inward rectifier potassium current (IK1) was acti-
vated from -40 mV to test potentials ranging from -20
to -120 mV in 10-mV steps for 1 s at a frequency of 0.1 Hz
under the infusion of CdCl2 (200 μM) and 4-aminopyridineffects of isoproterenol on control and leptin-treated left atrial
control (n = 22) LA myocytes and leptin-treated LA myocytes (n = 19).
l-induced DAD (★) from control and leptin-treated LA myocytes. The
reated (n = 21) LA myocytes. RMP resting membrane potential, APA action
otential duration, APD20 20% action potential duration. *p < 0.05 versus
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were measured as 1 mM barium-sensitive currents.
The NCX current was elicited by test potentials be-
tween -100 to +100 mV from a holding potential
of −40 mV for 300 ms at a frequency of 0.1 Hz. The am-
plitudes of the NCX current were measured as 10 mM
nickel-sensitive currents. The external solution (in mM)
consisted of NaCl 140, CaCl2 2, MgCl2 1, HEPES 5 and
glucose 10 with a pH of 7.4 and contained strophanthi-
din (10 μM), nitrendipine (10 μM) and niflumic acid
(100 μM).
Measurement of the changes in the intracellular calcium
concentration
The intracellular Ca2+ (Ca2+i) was recorded using a fluo-
rimetric ratio technique (indo-1 fluorescence) in an iso-
lated single leptin-treated and control LA myocyte, as
described previously [31,32]. The fluorescent indicator
indo-1 was loaded by incubating the myocytes at room
temperature for 20–30 min with 10 μM of indo-1/AM
(Sigma Chemical, St Louis, MO, USA). LA myocytes
were then perfused with Tyrode's solution at 35 ± 1°C
for at least 20 min to wash out the extracellular indica-
tor and to allow for the intracellular de-esterification of
the indo-1. The background and cell autofluorescence
were canceled out by zeroing the output of the photo-
multiplier tubes using cells without indo-1 loading. AFigure 2 Effects of leptin on sodium current (INa) and late sodium cur
relationship of the INa from control (n = 21) and leptin-treated (n = 14) LA
protocols. B. Examples and the average data of the INa-Late in control (n
LA myocytes.UV light of 360 nm with a monochromator was used for
the excitation of the indo-1 from a xenon arc lamp con-
trolled by the microfluorimetry system (OSP100-CA,
Olympus, Tokyo, Japan) and the excitation light beam was
directed into an inverted microscope (IX-70, Olympus,
Tokyo, Japan). The emitted fluorescence signals from the
indo-1/AM loaded myocytes were digitized at 200 Hz.
The ratio of the fluorescence emission at 410 and 485 nm
(R410/485) was used as the index of the Ca2+i. This
approach avoided any uncertainties resulting from
the calibration of the fluorescent Ca2+ indicators. The
Ca2+i transients were measured during a 2 Hz field
stimulation with 10 ms square-wave pulses at double
threshold strength and were calculated from the difference
of the peak systolic and diastolic Ca2+i transients. The
fluorescence ratio data were processed and stored on a
computer using the relevant software (OSP-SFCA, Olympus,
Tokyo, Japan). The sarcoplasmic reticulum (SR) Ca2+ con-
tent was estimated by adding 20 mM of caffeine after electric
stimulation at 2 Hz for at least 30 s. The total SR Ca2+ con-
tent was measured from the peak amplitude of the caffeine-
induced Ca2+i transients. We also measured the SR Ca
2+
content by integrating the NCX current from rapidly add-
ing 20 mM of caffeine to the cells during rest with the
membrane potential clamped to -40 mV. The time inte-
gral of the NCX current was converted to amoles of Ca2+
released from the SR [31].rent (INa-Late) in left atrial (LA) myocytes. A. Examples and the I–V
myocytes. The insets in the current traces show the various clamp
= 8) and leptin-treated myocytes (n = 8). ***p < 0.005 versus control
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All continuous variables are expressed as the mean ±
SEM. The differences between the control and the
leptin-treated LA myocytes were compared using the
Mann-Whiteney rank sum test or unpaired t-test de-
pending on the outcome of the normality test. A p value
of less than 0.05 was considered statistically significant.
Results
Effects of leptin on the electrical activity of LA myocytes
Figure 1A shows the AP morphology from the control
and the leptin-treated LA myocytes. The leptin-treated
LA myocytes had longer APD20, but similar APD50,
APD90, and RMP, compared to the control. Moreover,
the difference between APD90 and APD20 (ΔAPD90-20)
was smaller in the leptin-treated LA myocytes than in
the control LA myocytes. In the presence of iso-
proterenol (10 nM), leptin- treated LA myocytes exhib-
ited a lower incidence of DADs than the control myocytes
(Figure 1B).
Effects of leptin on the membrane currents of LA
myocytes
Compared to the control LA myocytes, the leptin-
treated LA myocytes exhibited larger INa (Figure 2A)
with a 46% increase of peak current (elicited from -120
to -40 mV). Both the control and the leptin-treated LA
myocytes exhibited similar INa-Late (Figure 2B) andFigure 3 Effects of leptin on the L-type calcium channel (ICa-L)
in left atrial (LA) myocytes. The current traces and I–V relationship
of ICa-L from control (n = 14) and leptin-treated (n = 10) LA myocytes.
The insets in the current traces show the various clamp protocols.similar ICa-L (Figure 3). The forward and reverse mode
of NCX currents were smaller in the leptin-treated LA
myocytes (Figure 4) than in the control myocytes with a
37.6% decrease in peak current (elicited from -40
to -100 mV) in the forward mode and a 51% decrease in
peak current (elicited from -40 to 100 mV) in the re-
verse mode.
As compared to the control myocytes, the leptin-
treated LA myocytes exhibited similar Ito, but smaller IKur
with a 32% decrease of peak current (elicited from -50 to
60 mV) (Figure 5A and 5B). The leptin-treated and con-
trol myocytes exhibited similar IK1 (Figure 5C).Effects of leptin on calcium handling of LA myocytes
As shown in Figure 6A, the leptin-treated LA myocytes
exhibited a smaller amplitude of Ca2+i transients than
the control myocytes. In addition, the leptin-treated LA
myocytes exhibited a smaller caffeine-induced Ca2+i
transients than the control myocytes, which was in con-
sistent with a reduced sarcoplasmic reticulum (SR) Ca2+
content from integrating caffeine-induced NCX current in
the leptin-treated LA myocytes (Figure 6B).Figure 4 The current tracings, I–V relationship of the nickel-sensitive
Na+–Ca2+ exchanger (NCX) currents in the control (n = 14) and
leptin-treated LA myocytes (n =14). The leptin-treated LA myocytes
have significantly smaller nickel-sensitive NCX currents than the control LA
myocytes do. The insets in the current traces show the various
clamp protocols. *p < 0.05; ***p < 0.005 versus control LA myocytes.
Figure 5 Effects of leptin on the transient outward current (Ito), the ultra-rapid delayed rectifier potassium current (IKur) and the inward
rectifier potassium current (IK1) in left atrial (LA) myocytes. A. Examples and I–V relationship of the Ito from control (n = 11) and leptin-treated
(n = 16) LA myocytes. B. Examples and I–V relationship of the IKur from control (n = 12) and leptin-treated (n = 14) LA myocytes. C. Examples and
the I–V relationship of the IK1 from control (n = 8) and leptin-treated (n = 10) LA myocytes. The inset in the current traces shows the clamp
protocol. *p < 0.05; ***p < 0.005 versus control LA myocytes.
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Obesity is characterized by leptin resistance, which is
additionally associated with chamber dilatation, dysfunc-
tion and increased risk of heart failure [33]. Adipose tis-
sue is a large endocrine organ that secretes numerous
adipokines. The effects of leptin on the heart are more
pronounced in cases of metabolic syndrome or obesity,
where it primarily acts systemically in visceral fat or acts
locally through either direct interactions or through
paracrine mechanisms in pericardial fat [10-12]. Leptin,
one of the adipokines, is secreted by adipocytes as well
as by cardiomyocytes and endothelial cells [13-16]. Lep-
tin may regulate the physiology of the heart including
myocyte contractility and metabolism [30], which both
influences cardiac electrophysiology.
In this study, we found that leptin-treated LA myo-
cytes had a longer APD20 and a shorter ΔAPD90-20. The
inhomogeneously prolonged AP duration (triangulation)
had been proposed as an arrhythmogenic factor [34].
Therefore, the increase of APD20 and the decrease of
ΔAPD90-20 may provide an anti-arrhythmic effect by
reverse-triangulation of AP. Additionally, as compared
to the control, we observed that leptin- treated LAmyocytes exhibited a lower incidence of isoproterenol-
induced DAD than the control did, which suggests that
leptin has potential anti-arrhythmic effects. Isoproter-
neol has been shown to increase several potassium cur-
rents [35-37], which can result in the shortening of AP
duration in control and leptin-treated myocytes. How-
ever, a previous study had revealed that epicardial fat
can prolong the AP duration, and positively shift RMP,
and increased isoproterenol-induced arrhythmogenesis
[11]. Our findings suggest that leptin may not be respon-
sible for arrhythmogenesis of adipose tissue. In contrast,
we propose that leptin attenuates the effects of adipose
arrhythmogenesis. Obesity amplifies the production of
multiple adipokines, and it is possible that adipokines
may offset the anti-arrhythmogeneic potentials of leptin,
thereby increasing the risks of AF in obesity. In addition,
leptin resistance has been suggested to impair the bene-
ficial effects of leptin [38].
We found that the INa current density in the leptin-
treated LA myocytes was significantly larger than that of
the control LA myocytes. Increasing fast INa may im-
prove conduction properties in cardiac cells, and thus
reduce the risk of conduction block [39]. In contrast, the
Figure 6 Effects of leptin on the intracellular Ca2+ and sarcoplasmic reticulum Ca2+ content of the LA myocytes. A. The tracings and
average data from the Ca2+ transient and caffeine-induced Ca2+ transient in the control (n = 42) and leptin-treated LA myocytes (n = 38). B. The
tracings of the caffeine-induced NCX currents and average data of SR Ca2+ content from integrating the NCX current in the control (n = 15) and
leptin-treated LA myocytes (n = 11). *p < 0.05 versus the control.
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treated LA myocytes. INa-Late was demonstrated to play a
vital role in the arrhythmogenic potentials of the atria
[40]. The larger INa but similar INa-Late in leptin-treated
LA myocytes suggests a favorable role of leptin on atrial
arrhythmogenesis.
NCX plays a critical role in the atrial arrhythmogenesis
[41]. In this study, we found that leptin-treated LA myo-
cytes exhibited reduced NCX. The leptin-treated LA
myocytes also exhibited smaller Ca2+i transient and
smaller SR content than the control myocytes, which
was in consistent with the known effects of leptin on
ventricular myocytes [30]. The observed Ca2+i transient
and SR Ca2+ content reduction in leptin-treated LA
myocytes may be caused by the suppression of NCXwith leptin. Leptin has been shown to increase the pro-
duction of nitric oxide [42], which exerts cardiac-
depressive actions. Therefore, the nitric oxide-mediated
electrophysiological effect plays a role in leptin’s reduc-
tion of Ca2+i transient and SR Ca
2+ content. Further-
more, the effects of leptin on calcium regulations may
attenuate the isoproterenol-induced arrhythmogenesis
by decreasing the genesis of the DAD.
IKur are atrial specific ionic currents and plays an im-
portant role in atrial arrhythmogenesis [43]. We found
that the leptin-treated LA exhibited smaller IKur, which
may produce a larger APD20 and a smaller ΔAPD90-20.
These effects may also contribute to an anti-AF poten-
tial. However, the IK1 was similar between the control
and the leptin-treated LA myocytes, which may account
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ventricular myocytes incubated with leptin (100 ng/ml)
for 48 hours have been shown to increase the expres-
sions of Ito α-subunits (Kv4.2, Kv4.3) and Kv channel
interacting protein (KChIP2), this study found that incu-
bation of leptin at 100 nM for a short period did not
change Ito in atrial myocytes [44].
Potential limitations
The data in this study should be interpreted with cau-
tion because of its potential limitations. First, similar to
those in the previous studies, this short-period experiment
has used a supra-physiological concentration (100 nM) of
leptin, which is higher than the clinically relevant concen-
trations [30]. The supra-physiological level of leptin may
potentially reduce body weight through systemic adminis-
tration of leptin in animal experiments [45,46]. Second,
the incubation time was only 1 h, which represents an
acute effect of leptin. A longer incubation time might yield
distinct results. In addition, only healthy atria tissue was
used in this study, the results may differ in diseased atrial
tissues. Finally, the underling molecular mechanisms for
the electrophysiological effects were not elucidated in this
study. JAK/STAT signaling had been suggested to play a
role in the cardiac effects of leptin [47,48]. However, it is
not clear whether the prolongation of APD20 or the
increase of INa can be blocked by JAK2 inhibition.
Conclusions
Leptin regulates the LA electrophysiological characteris-
tics and calcium homeostasis. Leptin attenuates the ef-
fect of isoproterenol-induced arrhythmogenesis, which
may play a favorable role in the pathophysiology of atrial
arrhythmogenesis.
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